Genevieve Levesque

ADVOCATE FOR IMPROVED AWARENESS, PREVENTION AND MANAGEMENT OF WOMEN'S HEART AND BRAIN HEALTH RISK FACTORS THROUGH BILL S-243, AN ACT TO ESTABLISH A NATIONAL FRAMEWORK FOR WOMEN'S HEALTH IN CANADA ADVOCATE FOR A MODERNIZED CHARITABLE TAXATION FRAMEWORK THAT STRENGTHENS CHARITIES AND THEIR ABILITY TO MOBILIZE RESOURCES FOR THE BENEFIT OF CANADIANS. FINALIZE REGULATIONS TO RESTRICT VAPE FLAVOURS (INCLUDING MINT/MENTHOL); INTRODUCE PLAIN AND STANDARDIZED PACKAGING FOR VAPING PRODUCTS; INCREASE TOBACCO AND VAPE TAXES; IMPLEMENT A TOBACCO COST RECOVERY FEE; PROTECT EXISTING NICOTINE POUCH REGULATIONS; BAN INTERNET/ONLINE SALES FOR TOBACCO AND E-CIGARETTES; PROHIBIT THE SALE OF TOBACCO PRODUCTS AMONGST INDIVIDUALS BORN BEFORE A DETERMINED YEAR; INCREASE THE MINIMUM LEGAL AGE OF SALE FOR TOBACCO AND VAPING PRODUCTS TO 21 YEARS OF AGE. SUPPORT POLICIES THAT ELIMINATE FINANCIAL BARRIERS TO SPORT PARTICIPATION FOR CHILDREN AND YOUTH, WHILE ENSURING SPORT PARTICIPATION FUNDING IS ROLLED OUT IN AN ACCESSIBLE, EQUITABLE, AND INCLUSIVE MANNER. ADVOCATE FOR GOVERNMENT ACTION TO REDUCE THE CONSUMPTION OF, AND HARMS ASSOCIATED WITH, ULTRA-PROCESSED FOODS. ADVOCATE FOR AND FUND EQUITABLE ACCESS TO PALLIATIVE CARE PROGRAMS FOR CANADIANS, INCLUDING EQUITY-SEEKING GROUPS. INTRODUCTION OF A NATIONAL PHARMACARE PROGRAM IMPLEMENT REGULATIONS TO RESTRICT COMMERCIAL MARKETING OF UNHEALTHY FOODS AND BEVERAGES TO CHILDREN IMPLEMENT A TAX ON SUGARY DRINKS. REVENUES FROM SUCH A TAXATION STREAM SHOULD BE USED TO SUBSIDIZE HEALTHY EATING INITIATIVES FUND PUBLIC AWARENESS FOR IMPROVED USE OF DEFIBRILLATORS AND CPR. ADVOCATE FOR A TAX-EXEMPTION ON THE SALE OF DEFIBRILLATORS. ENSURE THAT THE DEDICATED FEDERAL ACTIVE TRANSPORTATION INFRASTRUCTURE FUND BECOMES A PERMANENT ENVELOPE IN CANADA'S INFRASTRUCTURE FUNDING.

Support the inclusion of human rights objectives by Canada in international fora Promoting the importance of the full range of sexual and reproductive health and rights in development assistance programming, in line with a human rights framework and best practices. This can include conversations about accountability frameworks, funding practices, and resourcing international development assistance Discussions with government (department TBD) to support a national strategy for comprehensive sexuality education, including gender-based violence education, and access to accurate sexual and reproductive health information in Canada and in the world. This might also include requests for funding to support this advocacy work. Discussions with government (department TBD) to improve access to contraceptives in Canada and internationally. This could include changes to policies and programmes as well as requests for funds for further advocacy or services in this area. Discussions with government (department TBD) to discuss policies and programmes that would increase access to abortions for people in Canada and globally. This could include requests for funding related to supporting abortion access, proposed regulations and proposed legislation.

To familiarize Parliamentarians and senior public sector officials with the work undertaken by the 26 member institutions that comprise CAZA.

The CHC supports the establishment of a national pharamcare program, based on the recommendations contained in the Final Report of the Advisory Council on the Implementation of National Pharmacare (2019). The CHC supports the establishment of national standards for long term care, supported through conditional federal financial funding. The CHC supports the Canada Health Act and the enforcement of its provisions by the federal government using its spending authority. The CHC support Canada's voluntary-collection system for blood and blood products, including plasma. It opposes the paid-collection of blood and blood products.

Clean electricity regulations and emissions cap Investing in Employment Insurance, care workers, unionized jobs and strong workplace standards Addressing the high cost of living and investing in affordable housing Implementation of universal pharmacare, dental care, long term care and mental health care Labour provisions in the Canada-Ecuador Trade Agreement and Canada-United States-Mexico Agreement. The regularization of undocumented workers, update and possible next steps for the CLC Out-of-status Construction Workers in the GTA project Bill C-65, Canada Elections Act With interest in provisions that impact Third Parties and contributions to Third Parties Bill C-27, Digitial Charter Implementation Act - Part III of C-27 and the impact of artificial intelligence on jobs and workers.

Advocate for changes to facilitate adoption of auto features for retirement savings. Advocate for legislative or regulatory changes to allow for automatic features in workplace pension plans. Discussions related to the implementation of CRA Notice 344 Consultation on the National Strategy on mental health of men and boys Discussions related to Bill S-5 Connected Care for Canadians Act. FCAC direction to update complaint-handling information for insurers Discussions related to drug pricing, including decisions, policies and processes of the Patented Medicine Prices Review Board (PMPRB) Discussions related to supply and shortages of drugs in Canada, including the Multi-Stakeholder Steering Committee. Discussions related to regulatory burden, including “cutting red tape”. Impacts on Canadian insurers of proposed U.S. tax measures. Discussions relating to the efficiency and effectiveness of the financial sector regulatory system as it pertains to insurance companies. Discussing plans on the Data Collection Modernization initiative Promotion of a broader range of investments by insurance companies (e.g., farmland, timberland, fintechs) Statutory review of the Insurance Companies Act as it relates to insurance products and investments. Discussions related to the implementation of national pharmacare including bilateral agreements with provinces and territories; the committee of experts on the implementation of pharmacare and the advisory panel on bulk purchasing. Promotion of pension products, including decumulation solutions. Discussions related to the implementation of the Interpretation letter on the Canada health act related to physician equivalent services. Inter-provincial harmonization and trade barriers as it relates to insurance products. Discussions related to the financial sector policy review. Office of the Superintendent of Financial Institutions (OSFI). Guidelines related to risk management, capital and accounting for insurance companies. This includes capital charges for infrastructure investments under the LICAT. International Trade with respect to opening trade relations, regulations, foreign ownership and national treatment in foreign markets, with regards to India, Europe, China, Japan, Trans-Pacific partnership (TPP), Canada-United States-Mexico Agreement (CUSMA), Plurilateral Trade In Services Agreement (TISA) and the World Trade Organization (WTO). Work to ensure that the income tax act does not put insurance companies at a competitive disadvantage. Promotion of risk-based and principles-based regulation for financial institutions regulations. Personal Information Protection and Electronic Documents Act: seeking workable approaches to privacy rules affecting life and health insurers when the Act is updated. Income Tax Regulations (section 6(1)(f) as it relates to income tax withholding on wage loss replacement plans (disability income benefits). Income Tax Regulations, Part XIV. Income Tax Regulations, Part III: Updating income tax rules for life insurance policies. Income Tax Act, Section 146: Retirement income recommendations regarding the treatment of life insurance companies; Section 146.2 (TFSAs); Section 146.3 (RRIFs). Income Tax Act, Part VI as it relates to capital tax on financial institutions. Financing infrastructure projects, as it relates to investments by insurers Financial Transactions and Reports Analysis Centre of Canada (FINTRAC) risk-based guidance as it relates to life insurance Employment Insurance (EI) reform as it relates to disability benefits; and EI Premium Reduction Program issues. Amendments to Proceeds of Crime (Money Laundering) and Terrorist Financing rules as they affect insurance companies

Canada's Drug Agency policies as it relates to reimbursement recommendation decision-making process and framework Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry. Federal policies that relate to possible models of pharmacare Federal Buy Canadian Procurement Policy as it relates to government drug procurement practices and the implications for the biopharmaceutical industry Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations National Strategy for Drugs for Rare Diseases World Trade Organization (WTO) issues concerning the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility" World Intellectual Property Organization (WIPO) issues concerning the biopharmaceutical industry World Health Organization (WHO) issues concerning the biopharmaceutical industry Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB) Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products Income Tax Act as it relates to biopharmaceutical products Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry Free trade agreements as they relate to the biopharmaceutical industry Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry